Pharma
Pharma Strategic Planning & Portfolio Analytics
Pharma strategic planning analytics breaks when IMS or proxy market files, launch trackers, and finance price decks refresh on different calendars. Therapy area priority scoring looks objective until one fast-growing class hides thin coverage, tender drag, and competitive entries that a national index does not show. New molecule launch readiness fragments across CMC dates, label assumptions, and field ramp plans so leadership debates readiness without a single scorecard. Rx drop stories emerge in war rooms, but the rx drop causal chain from access, share loss, and stock to true demand stays argued without one trace. Pricing scenario modeling pharma turns fragile when list price, hospital nets, and patient programs sit in different models and no one shows volume elasticity on the same base.
FireAI joins approved market and internal Rx or proxy layers, launch gate data, access and stock signals, and your pricing levers with guardrails so pharma strategic planning analytics answers which therapy areas deserve the next billion of investment, whether new molecule launch readiness matches supply and first-wave coverage, what the rx drop causal chain says when share and access both move, and how pricing scenario modeling pharma lands on margin under realistic share and access paths.
The domain covers therapy area priority scoring, new molecule launch readiness, causal analysis when Rx falls, and what-if pricing scenarios, through chat, dashboards, and causal chains strategy and brand leadership can use in the same review. See how it works: get a demo.
Therapy area priority scoring
Therapy area priority scoring that ranks only on current Rx or revenue misses where next-year growth and competitive risk actually sit. A hot class can look attractive on paper while access delays, new entrants, and tender erosion compress the window you have to win.
FireAI scores each therapy family on market potential, unmet need proxy, your relative strength, access friction, and pipeline or lifecycle crowding. Therapy area priority scoring produces a clear stack with explicit weights leadership agrees to update each cycle so portfolio and brand teams do not re-litigate the math in every meeting.
How FireAI solves the problem: It stores versioned weight sets, shows sensitivity when one driver changes, and links each area to the underlying metrics so strategy can defend the list to the board in one place.
What FireAI tracks:
- Composite priority index by therapy with component contributions
- Trend versus prior cycle for market attractiveness and your position
- Access and tender risk flags that de-prioritize raw growth
- Overlap and cannibalization signals where two brands compete in the same class
Leadership uses therapy area priority scoring inside pharma strategic planning analytics to set resource and launch sequencing before budgets freeze.
Priority stack cockpit
New molecule launch readiness
New molecule launch readiness fails when CMC, regulatory, label, and field dates live in different project systems and no one number says “ready to file” versus “ready to sell.” Launches slip or start soft when supply buffers, KOL plans, and stockist first-fill are not on one timeline.
FireAI assembles launch gates, dependent milestones, and risk status from the sources you connect, with manual overrides and owners where needed. New molecule launch readiness shows red-amber-green by workstream, critical path weeks, and confidence labels when dates are still fuzzy.
How FireAI solves the problem: It drives one readiness score per wave with auditable changes, so strategy and brand align on go or delay without a separate offline tracker.
What FireAI tracks:
- Gate completion versus plan by regulatory, CMC, market access, and field
- Buffer days on supply and first distributor stock for wave one cities
- Label or pricing assumption flags that change the revenue case
- Parallel scenarios when one gate slips a quarter
Portfolio teams use new molecule launch readiness with pharma strategic planning analytics to stage capital and pre-launch marketing without surprise overlap.
Ask FireAI about launch readiness
See how your team can ask questions in plain language and get instant analytics answers.
Causal chain: why did Rx drop?
Rx decline reviews argue over IMS noise, detailling gaps, and stock before anyone agrees on the rx drop causal chain that matters. A national dip can hide a tender loss in a few states while the field still shows healthy calls.
FireAI decomposes change into access, share within available demand, and fulfillment where data supports, then lets leadership test narratives against the same structure. A clear rx drop causal chain stops the meeting from defaulting to “competitor buzz” with no way to test or act.
How FireAI solves the problem: It pins each layer to the feeds and time windows you approve, labels confidence where the panel is thin, and links recommended plays to the dominant driver.
What FireAI tracks:
- Access and tender event overlay versus Rx or proxy change
- Share shift versus key competitors in matched geographies
- Stock and distribution exception correlation with short-term Rx noise
- Field activity change only after ruling out the above where policy allows
Executives use the rx drop causal chain inside pharma strategic planning analytics to choose price, access, or field fixes without guessing the cause.
Causal chain: Rx fall
What-if pricing scenario modeling
Pricing scenario modeling pharma often lives in static Excel where list price, net to hospital, and stockist terms never meet the same demand curve. A headline increase looks good until access teams show tender exclusions and realizable volume.
FireAI links price levers to approved elasticity bands, channel mix, and access rules you maintain. Pricing scenario modeling pharma shows margin, volume, and share outcomes under list change, cap programs, and tender-specific nets side by side.
How FireAI solves the problem: It versions assumptions with owner and date, and surfaces break-even curves so strategy does not re-open the file every time one competitor moves.
What FireAI tracks:
- Revenue, contribution, and access-covered volume under each scenario
- Sensitivity to elasticity and share retention assumptions
- Downside cases when a tender rejects the new price band
- Comparison to the prior-year realized net as a sanity check
Finance and brand use pricing scenario modeling pharma within pharma strategic planning analytics to set targets governance can defend.